Deon Bryant Doxie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Deon Bryant Doxie has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Kavita M. Dhodapkar
Emory University 9 Department of Pediatrics Atlanta, Georgia
55 shared publications - Bassel F. El-Rayes
Division of Hematology and Oncology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
42 shared publications - Chrystal M. Paulos
Winship Cancer Institute, Emory University
42 shared publications - Emily Greene
Department of Hematology & Medical Oncology, Emory University, Atlanta, USA
42 shared publications - Erin E. Grundy
Department of Hematology & Medical Oncology, Emory University, Atlanta, USA
42 shared publications - Gregory B. Lesinski
Emory University
42 shared publications
Latest Publications
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
MIF confirms that fibroblast and macrophage populations differ between primary and metastatic PDAC. A, Representative images of Picrosirius Red–stained samples under brightfield and polarized light. Scale bar, 100 μm. B, Truncated violin plot quantifying percentage tissue area positive for Picrosirius Red staining. Sample size: primary, n = 23; metastatic, n = 13. C, Representative mIF fibroblast panel detecting αSMA (white), PDGFRβ (red), and PDPLN (green). Scale bar, 100 μm. D, Stacked bar graph showing the percent of total αSMA+ phenotyped cells in primary and metastatic tumors (not significant). E, Truncated violin plot quantifying PDGFRβ+-only and PDPLN+-only cells. Sample size: primary, n = 18; metastatic, n = 11. F, Representative mIF macrophage panel detecting CD68 (white), CD163 (red), and CCR2 (green). Scale bar, 500 μm. G, Truncated violin plots quantifying CD68+-only CD68+CCR2+ and CD163+-only as a percentage of total cells. Sample size: primary, n = 20; metastatic, n = 12. B, E, and G, Statistical analysis was performed using Mann–Whitney test; D, statistical analysis was performed using two-way ANOVA.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
MIF confirms that fibroblast and macrophage populations differ between primary and metastatic PDAC. A, Representative images of Picrosirius Red–stained samples under brightfield and polarized light. Scale bar, 100 μm. B, Truncated violin plot quantifying percentage tissue area positive for Picrosirius Red staining. Sample size: primary, n = 23; metastatic, n = 13. C, Representative mIF fibroblast panel detecting αSMA (white), PDGFRβ (red), and PDPLN (green). Scale bar, 100 μm. D, Stacked bar graph showing the percent of total αSMA+ phenotyped cells in primary and metastatic tumors (not significant). E, Truncated violin plot quantifying PDGFRβ+-only and PDPLN+-only cells. Sample size: primary, n = 18; metastatic, n = 11. F, Representative mIF macrophage panel detecting CD68 (white), CD163 (red), and CCR2 (green). Scale bar, 500 μm. G, Truncated violin plots quantifying CD68+-only CD68+CCR2+ and CD163+-only as a percentage of total cells. Sample size: primary, n = 20; metastatic, n = 12. B, E, and G, Statistical analysis was performed using Mann–Whitney test; D, statistical analysis was performed using two-way ANOVA.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Additional multiplex IHC antibodies
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Additional multiplex IHC antibodies
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 9 from High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Percent of cells in each tumor structure
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 9 from High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Percent of cells in each tumor structure
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Patient sample workflow: acquisition, processing, and data analysis. Flow chart illustrating (1) the total number of samples acquired per tumor type, (2) the number processed via histology or CyTOF, and (3) the final number included for data analysis in this study based on minimum cell count criteria. Created in BioRender. Lesinski, G. (2025) https://BioRender.com/w97c106.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Patient sample workflow: acquisition, processing, and data analysis. Flow chart illustrating (1) the total number of samples acquired per tumor type, (2) the number processed via histology or CyTOF, and (3) the final number included for data analysis in this study based on minimum cell count criteria. Created in BioRender. Lesinski, G. (2025) https://BioRender.com/w97c106.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 15 from High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Opt_SNE plots of checkpoint marker expression on CD4+ and CD8+ T cells
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 15 from High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Opt_SNE plots of checkpoint marker expression on CD4+ and CD8+ T cells
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 16 from High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Matched primary and metastatic PDAC samples validates trends observed in the larger cohort analysis
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 16 from High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Matched primary and metastatic PDAC samples validates trends observed in the larger cohort analysis
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 13 from High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Mass cytometry analysis of T cell subsets in primary and metastatic PDAC
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 13 from High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Mass cytometry analysis of T cell subsets in primary and metastatic PDAC